nach oben

Erschienen in:

01.07.2006 | Original Article

Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells

verfasst von: Eileen Brantley, Smitha Antony, Glenda Kohlhagen, LingHua Meng, Keli Agama, Sherman F. Stinson, Edward A. Sausville, Yves Pommier

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose: The fluorinated benzothiazole analogue 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) exhibits selective and potent anticancer activity, and its lysylamide prodrug (Phortress, NSC 710305) recently entered Phase I clinical trials in the United Kingdom. Only cancer cells sensitive to the anti-proliferative effects of 5F 203 deplete this drug candidate from nutrient media. 5F 203 induces cell cycle arrest, cytochrome P450 1A1 (CYP 1A1) mRNA and protein expression, and is metabolized into reactive electrophilic species that can covalently bind to DNA and form adducts in sensitive (i.e., MCF-7) but not in resistant (i.e., MDA-MB-435) breast cancer cells. Methods: In this present study, we investigated additional anticancer effects of 5F 203 in MCF-7 cells. In addition, we sought to determine if cells deficient in the xeroderma pigmentosum D gene, a gene critical in DNA repair, would show greater sensitivity to the cytotoxic effects of 5F 203 than those complemented with XPD. Results: Alkaline Elution revealed that 5F 203 induced single-strand breaks and DNA-protein cross-links in sensitive MCF-7 cells. In contrast, we detected no double-strand breaks or protein-associated strand breaks typically associated with topoisomerase I (top1) or topoisomerase II (top2) inhibition. In addition, 5F 203 was unable to trap top1- or top2-DNA cleavage complexes in MCF-7 cells. 5F 203 induced cell cycle arrest in MCF-7 cells following DNA damage after brief exposures. Cells deficient in the nucleotide excision repair xeroderma pigmentosum group D (XPD) gene displayed sensitivity to 5F 203 while cells complemented with XPD displayed resistance to 5F 203. Conclusion: These data suggest that the anti-cancer activity of 5F 203 depends upon targets other than top1 or top2 and on the ability of this benzothiazole to form single-strand breaks and DNA-protein cross-links in cancer cells.

Acton EM, Narayanan VL, Risbood PA, Shoemaker RH, Vistica DT, Boyd MR (1994) Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. J Med Chem 37:2185–2189PubMedCrossRef

Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589–601PubMed

Arima Y, Hirota T, Bronner C, Mousli M, Fujiwara T, Niwa S, Ishikawa H, Saya H (2004) Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 9:131–142PubMedCrossRef

Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y (1991) Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 51:6280–6285PubMed

Boulikas T, Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level (Review). Oncol Rep 10:1663–1682PubMed

Brantley E, Trapani V, Alley MC, Hose CD, Bradshaw TD, Stevens MF, Sausville EA, Stinson SF (2004) Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug Metab Dispos 32:1392–1401PubMedCrossRef

Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MF (2000) Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 60:5196–5203PubMed

Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899–4902PubMed

Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C (2002) Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 97:439–445PubMedCrossRef

10.

Gibson NW, Hartley JA, Strong JM, Kohn KW (1986) 2-Chloroethyl (methylsulfonyl)methanesulfonate (NSC-338947), a more selective DNA alkylating agent than the chloroethylnitrosoureas. Cancer Res 46:553–557PubMed

11.

Hose CD, Hollingshead M, Sausville EA, Monks A (2003) Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity. Mol Cancer Ther 2:1265–1272PubMed

12.

Hutchinson I, Chua MS, Browne HL, Trapani V, Bradshaw TD, Westwell AD, Stevens MF (2001) Antitumor benzothiazoles 14 Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 44:1446–1455PubMedCrossRef

13.

Jensen PB, Sorensen BS, Demant EJ, Sehested M, Jensen PS, Vindelov L, Hansen HH (1990) Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 50:3311–3316PubMed

14.

Johnson DE, Ochieng J, Evans SL (1996) Phenylacetic acid halides inhibit estrogen receptor (ER)-positive MCF-7 cells, but not ER-negative human breast cancer cells or normal breast epithelial cells. Anticancer Drugs 7:288–292PubMedCrossRef

15.

Kashiyama E, Hutchinson I, Chua MS, Stinson SF, Phillips LR, Kaur G, Sausville EA, Bradshaw TD, Westwell AD, Stevens MF (1999) Antitumor benzothiazoles 8 synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles. J Med Chem 42:4172–4184PubMedCrossRef

16.

Khan QA, Kohlhagen G, Marshall R, Austin CA, Kalena GP, Kroth H, Sayer JM, Jerina DM, Pommier Y (2003) Position-specific trapping of topoisomerase II by benzo[a]pyrene diol epoxide adducts: implications for interactions with intercalating anticancer agents. Proc Natl Acad Sci USA 100:12498–12503PubMedCrossRef

17.

Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM (2002) Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 62:143–153PubMedCrossRef

18.

Leong CO, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC, Cooper PA, Double JA, Bradshaw TD, Stevens MFG (2003) Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br J Cancer 88:470–477PubMedCrossRef

19.

Leong CO, Suggitt M, Swaine DJ, Bibby MC, Stevens MFG, Bradshaw TD (2004) In vitro, in vivo and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol Cancer Ther 3:1565–1575PubMed

20.

Loaiza-Perez AI, Trapani V, Hose C, Singh SS, Trepel JB, Stevens MF, Bradshaw TD, Sausville EA (2002) Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol 61:13–19PubMedCrossRef

21.

Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA (2004) Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 3:715–725PubMedCrossRef

22.

Meng LH, Kohlhagen G, Liao Zy, Antony S, Sausville E, Pommier Y (2005) DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res 65:5337–5343PubMedCrossRef

23.

Monks A, Harris E, Hose C, Connelly J, Sausville EA (2003) Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 63:766–772PubMedCrossRef

24.

O’Brien SE, Browne HL, Bradshaw TD, Westwell AD, Stevens MF, Laughton CA (2003) Antitumor benzothiazoles Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl)benzothiazoles to reactive intermediates by cytochrome P4501A1. Org Biomol Chem 1:493–497PubMedCrossRef

25.

Pobst LJ, Ames MM (2005) CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines. Cancer Chemother Pharmacol 11:1–8

26.

Pommier Y, Goldwasser F, Strumberg D (2001) (eds) Topoisomerase II inhibitors: epipodophyllotoxins, acridines, ellipticines, and bisdioxopiperazines. Lippincott Williams & Wilkins, Philadelphia

27.

Pommier Y, Kohlhagen G, Kohn KW, Leteurtre F, Wani MC, Wall ME (1995) Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA 92:8861–8865PubMedCrossRef

28.

Pommier Y, Sordet O, Rao VA, Zhang H, Kohn KW (2005) Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des 11:2855–2872PubMedCrossRef

29.

Reardon JT, Sancar A (2002) Molecular anatomy of the human excision nuclease assembled at sites of DNA damage. Mol Cell Biol 22:5938–5945PubMedCrossRef

30.

Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, Sausville EA (1999) Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem Pharmacol 57:1283–1295PubMedCrossRef

31.

Shao RG, Cao CX, Shimizu T, O’Connor PM, Kohn KW, Pommier Y (1997) Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 57:4029–4035PubMed

32.

Solary E, Leteurtre F, Paull KD, Scudiero D, Hamel E, Pommier Y (1993) Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem Pharmacol 45:2449–2456PubMedCrossRef

33.

Strumberg D, Pommier Y, Paull K, Jayaraman M, Nagafuji P, Cushman M (1999) Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J Med Chem 42:446–457PubMedCrossRef

34.

Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y (2001) Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 7:185–191PubMed

35.

Trapani V, Patel V, Leong CO, Ciolino HP, Yeh GC, Hose C, Trepel JB, Stevens MF, Sausville EA, Loaiza-Perez AI (2003) DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Br J Cancer 88:599–605PubMedCrossRef

36.

Urasaki Y, Takebayashi Y, Pommier Y (2000) Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. Cancer Res 60:6577–6580PubMed

37.

Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440PubMedCrossRef

38.

Wu X, Fan W, Xu S, Zhou Y (2003) Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res 9:5874–5879PubMed

39.

Zhelkovsky AM, Moore CL (1994) Overexpression of human DNA topoisomerase I in insect cells using a baculovirus vector. Protein Expr Purif 5:364–370PubMedCrossRef

Titel: Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells
verfasst von: Eileen Brantley
Smitha Antony
Glenda Kohlhagen
LingHua Meng
Keli Agama
Sherman F. Stinson
Edward A. Sausville
Yves Pommier
Publikationsdatum: 01.07.2006
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2006
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-005-0127-z

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells

Abstract

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Enforced expression of cytosolic 5′-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer

Chemoprotection effect of retroviral vector encoding multidrug resistance 1 gene to allow intensified chemotherapy in vivo

Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization

5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Update Onkologie